China permits human testing for COVID vaccine by Chongqing Zhifei


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ china-permits-human-testing-covid-vaccine-chongqing-zhifei
Developers obtained a certificate from the National Medical Products Administration to launch clinical trials

The origin-country of Coronavirus China is now ready to test its indigenous vaccine, developed by Chongqing Zhifei Biological Products’ unit, on human beings, the corporate said during a filing on Tuesday.
Anhui Zhifei Longcom Biopharmaceutical jointly developed the vaccine along with the Institute of Microbiology of the Chinese Academy of Sciences and has obtained a certificate from the National Medical Products Administration to launch clinical trials.
Chinese researchers and corporations are starting with six shots in humans, while over a dozen vaccines are in several stages of clinical trials across the globe against the virus that has claimed over 470,000 lives.
Meanwhile, US-based Moderna has finalized the Phase 3 study protocol, which includes approximately 30,000 participants enrolled within the US to check its COVID-19 vaccine's efficacy on a larger scale.
The randomized, placebo-controlled trial is predicted to start in July.


"The company remains on target to be ready to deliver approximately 500 million doses per annum, and possibly up to 1 billion doses per annum, beginning in 2021 from the company’s internal US manufacturing site and strategic collaboration with Lonza," the corporate is quoted from a handout it issued.
“We anticipate beginning our Phase 3 study of mRNA-1273," said Tal Zaks, MD, Ph.D., Chief medic at Moderna, pertaining to the COVID-19 vaccine's code name.
“Moderna is committed to advancing the clinical development of mRNA-1273 as safely and quickly as possible to demonstrate our vaccine’s ability to significantly reduce the danger of COVID-19 disease,” he added.


On May 11, the Food and Drug Administration (FDA) granted the new drug (IND) application for mRNA-1273.
The Phase 1 study is ongoing with the first cohorts in long-term follow-up and enrollment in 9 of 12 cohorts complete. The National Institutes of Health (NIH) are going to be submitting the Phase 1 data to a peer-reviewed clinical publication.
This Phase 2 study is evaluating the security, reactogenicity, and immunogenicity of two vaccinations of mRNA-1273 given 28 days apart.
There are about 160 vaccines that are under development with an aim to beat the Sars-Cov-2 coronavirus, which causes the COVID-19 disease. the continued pandemic has seen about 7.6 million people infected and has caused over 400,000 deaths.

Tags : #China #Vaccine #Coronavirus #COVID19 #US #HumanTesting

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026